NUVIGIL(TM) for the Treatment of Excessive Sleepiness

The FDA approved Armodafinil (Nuvigil®) on June 18, 2007 for the treatment of excessive sleepiness due to sleep apnea, narcolepsy or shift-work disorder (SWSD). Armodafinil (Nuvigil®) is an stimulant drug and is an improved version of Provigil (modafinil ®).

NUVIGIL is a federally controlled substance (C-IV) and is protected by a U.S. patent expiring in 2023 (U.S. Patent Nos. RE37, 516; 4,927,855)
.

Although NUVIGIL has not been shown to produce functional impairment, any drug
affecting the CNS may alter judgment, thinking or motor skills. Patients should be
cautioned about operating an automobile or other hazardous machinery until they are
reasonably certain that NUVIGIL therapy will not adversely affect their ability to engage
in such activities.